A combinatorial therapy for pancreatic cancer using mRNA-5671 (encoding K-Ras neoantigen) with KEYTRUDA (a PD-1 specific inhibitor) is currently under clinical trial [175]. Here, KRAS is linked to pancreatic neoplasm.